SciClone report positive hep C data

SciClone Pharmaceuticals and Sigma-Tau are reporting positive interim data from a Phase III trial of Zadaxin for hepatitis C. At the end of 48 weeks, the blinded data show that 171 out of 553 total patients, including both treatment and control group patients, responded to treatment. "These interim HCV data are promising because, although we do not know the breakdown between thymalfasin treated and control group patients who have achieved an SVR, this is already a strong overall response for nonresponder patients," said Mario Rizzetto, M.D., lead investigator of the trial. Full results of the trial will be available in the third quarter.

- see this release for more

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.